


Annual general meeting

Oslo, April 8 2010




The preferred partner

 **AkerBioMarine™**

part of Aker


Agenda

1. **Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair**
2. Ordinary items
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report.
 - 2.3. Determination of Board members' remuneration.
 - 2.4. Determination of Nomination Committee members' remuneration.
 - 2.5. Approval of auditors' fees.
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report.
 - 2.7. Election of Board members.
 - 2.8. Election of Nomination Committee members.
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 **Presentation of business activities**
 - 2.2 **Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report**
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase



Aker BioMarine overview



Krill



- Harvesting, production, documentation and sales & marketing

NOK 125m

Other

- Tonalin® / CLA royalty
- Pharmaceutical and Omega-3 Concentrate
- Holding functions

NOK 20m


The preferred partner



part of Aker

Highlights 2009

- **International break through in the US**
 - Aker BioMarine signed an exclusive supply agreement of Superba™ Krill with a market leader in US.
- **Superba™ Krill to be used in joint and eye health products**
 - Aker BioMarine signed a long-term global supply agreement for the use of Superba™ Krill in joint and eye health products.
- **Superba™ Krill ready for the European market**
 - Superba™ Krill approved as Novel Food in the European Union. Consequently, Superba™ Krill can be sold in all countries within the European Union.
- **Superba™ Krill more beneficial than fish oil**
 - A preclinical study was performed for Aker BioMarine in 2009, demonstrating that Superba™ Krill provides substantially more reduction of fat in the heart and the liver than omega-3 from fish oil.







The preferred partner

 **AkerBioMarine™**

Key performance indicators

2007 – 2009*



The preferred partner




Income statement 2009

| NOK million | 2009 | 2008 |
|---|-------------|-------------|
| Operating revenues | 145 | 85 |
| Cost of goods sold and changes in inventories | -63 | -9 |
| Salaries and payroll costs | -58 | -59 |
| Other operating expenses | -171 | -170 |
| Operating loss before depreciation, amortisation and impairments | -147 | -152 |
| Depreciation and amortisation | -63 | -55 |
| Impairments and other non-recurring items | -38 | 20 |
| Operating loss | -247 | -187 |
| Financial income | 64 | 294 |
| Financial expenses | -121 | -370 |
| Loss before tax | -304 | -263 |
| Taxes | 0 | -81 |
| Net loss from continuing operations | -304 | -344 |
| Discontinued operations | | |
| Profit/loss from discontinued operations (net of tax) | 0 | -86 |
| Net loss for the period | -304 | -431 |

Comments

- Revenue growth of NOK 60m
 - Superba™ Krill NOK 50m (0)
 - Qrill™ NOK 59m (53)
 - Royalty CLA NOK 15m (22)
- Costs
 - Higher cost of goods sold
 - Impairment on intangible assets




Balance sheet

| NOK million | 2009 | 2008 |
|--|--------------|--------------|
| ASSETS | | |
| Property, plant and equipment | 492 | 478 |
| Intangible assets | 496 | 524 |
| Interest-bearing long-term receivables | 0 | 563 |
| Total non-current assets | 989 | 1 565 |
| Inventories | 56 | 69 |
| Trade receivables and other non-interest-bearing receivables | 52 | 55 |
| Interest-bearing current receivables | 517 | 14 |
| Cash and cash equivalents | 8 | 220 |
| Total current assets | 633 | 359 |
| Total assets | 1 621 | 1 924 |
| EQUITY AND LIABILITIES | | |
| Share capital | 90 | 90 |
| Other restricted equity | 648 | 648 |
| Total paid-in equity | 738 | 738 |
| Translation differences and other reserves | 0 | 1 |
| Retained earnings | -543 | -240 |
| Total equity | 196 | 500 |
| Convertible debt | - | 370 |
| Interest-bearing long-term loans | 100 | 883 |
| Deferred tax | 0 | 0 |
| Pension liabilities | 4 | 3 |
| Other non-interest-bearing long-term liabilities | 1 | 7 |
| Total long-term liabilities | 105 | 1263 |
| Convertible debt | 422 | |
| Interest-bearing current liabilities | 839 | 15 |
| Trade and other payables | 60 | 146 |
| Total current liabilities | 1321 | 161 |
| Total liabilities | 1 426 | 1 437 |
| Total equity and liabilities | 1 621 | 1 924 |

The preferred partner

Comments

- 12 percent equity ratio
- Cash and cash equivalents of NOK 8m
- Total assets of NOK 1,6mrd
- Net interest bearing debt of NOK 836m
- Interest bearing assets and liabilities booked as short term due to refinancing plan




2.2. Proposed resolution

“The general meeting resolved to approve the annual accounts for 2009 for Aker BioMarine ASA, the group consolidated accounts and the annual report”




Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration**
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase




2.3 Proposed resolution

*“The nomination committee proposes the following remuneration for Board members for the period 2009-2010:
Board Chairman: NOK 300,000
Board members: NOK 200,000”*



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration**
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase




2.4 Proposed resolution

*“The following remuneration for nomination committee members is proposed for the period 2009-2010:
Chairman and members: NOK 30,000”*




Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees**
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase




2.5 Proposed resolution

“The general meeting approved the auditor’s fees of NOK 721 475 for the audit of Aker BioMarine ASA in 2009”



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report**
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase




2.6 Proposed resolution

“The general meeting resolved to endorse the Board of Directors’ statement included in note 30 to the consolidated accounts on page 42 of the annual report, and to approve the remuneration proposed by the Board”



Agenda


1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members**
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase



2.7 Proposed resolution


“The nomination committee proposes no changes to the board of directors”

Pursuant to the company’s articles of association, the Board is to comprise from three to nine Board members. The Board now comprises of five Board members. None of these are up for election this year



Agenda


1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members**
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase



2.8 Proposed resolution


“The nomination committee proposes no changes to the nomination committee”

No members of the nomination committee are up for election this year



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. **Ordinary items**
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting**
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase




2.9 Proposed resolution

“Until the annual general meeting in 2011 the Board of Directors may resolve to call an extraordinary shareholders’ meeting by issuance of a notice of general meeting to the shareholders within two weeks prior to the meeting”



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. Ordinary items
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
- 3. Amendments to Articles of Association**
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase



3. Proposed resolution

”Vedtektenes § 7 endret til å lyde:

*Selskapets firma tegnes av styrets leder alene eller to styremedlemmer i fellesskap hvorav minst en må være aksjonærvalgt”**

“Section 9 of the Articles of Association is amended as follows:

Notice of the General Meeting shall be made by written notification to all shareholders with a known address. Provided documents concerning items to be discussed at the General Meeting are made available at the company’s web-site, the requirement of mailing the documents to the shareholders does not apply. This also applies for documents which, according to the law, shall be included in or attached to the notice of General Meeting. Despite this, each shareholder is entitled to request that the documents concerning items to be discussed at the General Meeting are mailed.

The company may set a deadline in the Notice of General Meeting for registration of attendance to the General Meeting, which shall not fall earlier than five (5) days prior to the General Meeting.

The Board can decide that the shareholders shall be able to cast votes in writing, including by electronic communication, in a period prior to the General Meeting. For such voting an adequate method to authenticate the sender shall be used.


The Chairman of the Board or a person designated by him shall preside at the General Meeting. The Annual General Meeting shall discuss and decide on the following matters.

a) Approval of the annual accounts and the annual report, including distribution of dividend, if any.

b) Other matters that pursuant to law or the Articles of Association fall under the authority of the general meeting.


Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. Ordinary items
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
- 4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt**
5. Approval of Agreement with Aker ASA regarding guarantee
6. Capital Increase




4. Proposed resolution

“The annual general meeting approves the agreement with Aker ASA regarding the sale of receivables and the settlement of debt positions, and authorizes the Board of Directors to make minor changes to the agreement”



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. Ordinary items
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
- 5. Approval of Agreement with Aker ASA regarding guarantee**
6. Capital Increase




5. Proposed resolution

The annual general meeting approves the agreement regarding a guarantee from Aker ASA with the appurtenant mortgage agreements, and authorizes the Board of Directors to make minor changes to the agreement.”



Agenda

1. Opening of the annual general meeting and election of person to co-sign meeting minutes along with meeting chair
2. Ordinary items
 - 2.1 Presentation of business activities
 - 2.2 Approval of the 2009 annual accounts of Aker BioMarine ASA and consolidated accounts and the Board of Directors' Report
 - 2.3. Determination of Board members' remuneration
 - 2.4. Determination of Nomination Committee members' remuneration
 - 2.5. Approval of auditors' fees
 - 2.6. Handling of the Board of Directors' statement on the determination of salary and other remuneration to leading employees of the company. The statement is contained in note 30 to the consolidated accounts in the Annual Report
 - 2.7. Election of Board members
 - 2.8. Election of Nomination Committee members
 - 2.9. Reduced notice period of extraordinary general meeting
3. Amendments to Articles of Association
4. Approval of Agreement with Aker ASA regarding assignment of receivables and settlement of debt
5. Approval of Agreement with Aker ASA regarding guarantee
6. **Capital Increase**



6. Proposed resolution (i)

The Company's share capital shall be increased by no less than NOK 586,000,000 and no more than NOK 638,000,000 through share issue of no less than 586,000,000 and no more than 638,000,000 new shares, each with the nominal value of NOK 1. The subscription rate per share will be NOK 1, and share deposits shall be made in cash.

2. Shareholders in the Company at the end of 8 April 2010, who are duly registered as such in the Company's shareholders register with the Norwegian Central Securities Depository (VPS) at the end of 13 April 2010, will have priority rights at the subscription of shares, and will receive one (1) subscription right per 0.14124156897 share they are registered as holders of at the end of 13 April 2010. Shareholders acquiring shares 8 April or sooner, who are not registered in the Company's shareholder register in VPS by the end of 13 April 2010 will not be provided with subscription rights. Each subscription right gives right to subscribe for one (1) new share in the Company. Subscription rights are tradable. Fractional subscription rights will not be issued.

Aker Seafoods Holding AS will, at the execution of their subscription rights, maximum be allotted and considered to subscribe for shares according to the following formula:

The maximum number of allotted and purchased shares = $488,000,000 + (4.99000826856 \times (A - 98,000,000))$ in which A represents the total number of shares subscribed by investors and existing shareholders in the share issue except Aker Seafoods Holding AS. This implies that Aker Seafoods AS' subscription rights do not grant the right to be allotted and subscribe for more than 488,000,000 shares until at least 98,000,000 shares have been subscribed by other parties than Aker Seafoods Holding AS, and furthermore that Aker Seafoods Holding AS' subscription rights do not grant the right to be allotted more than 83.305532226 per cent of the shares beyond 586,000,000 shares. In the event that $A - 98,000,000$ represents a negative number, Aker Seafoods Holding AS' subscription rights grants the right to 488,000,000 shares.

3. Over-subscription and subscription without subscription rights are permitted.

The preferred partner

 **AkerBioMarine™**

part of Aker

6. Proposed resolution (ii)

4. Allocation of shares subscribed in the share issue is made by the Company's Board of Directors. The following allocation principles shall apply (with the modifications for Aker Seafoods Holding AS as described in section 2 above):

(i) Shares will be allotted to subscribers based on allotted and acquired subscription rights which are duly exercised during the subscription period.

(ii) In the event that not all issued subscription rights are exercised, subscribers who have subscribed on the basis of subscription rights and who have over-subscribed, will be allotted further new shares proportionally to the number of subscription rights they have exercised. If it is impossible to execute proportional allotment, the Company will allot shares by lottery.

(iii) New shares that have not been allotted in accordance with section (i) and (ii) above will be allotted to subscribers who do not hold subscription rights. Attempts will be made at allotting shares proportionally based on the respective subscription amounts, with proviso for rounding off of amounts.

5. The Company will prepare a prospectus to be approved by Oslo Børs in connection with the share issue. Unless the Board of Directors decides otherwise, the prospectus will not be registered with or approved by any foreign stock exchange authorities. New shares cannot be acquired by investors in jurisdictions in which the offering of new shares is prohibited. The Company or parties authorised by the Company may, for shareholders who in the view of the Company are not entitled to acquire new shares as a consequence of legal restrictions or other regulations in the jurisdiction where the share holder is residing or a citizen, sell the share holder's subscription rights for a transfer of the net proceeds at the sale to the shareholder.

6. Proposed resolution (iii)

6. The subscription period will commence on 15 April 2010 and expire on 29 April at 17:30h (Oslo time). In the event that the prospectus has not been approved before the intended commencement of the subscription period, the subscription period will commence on the fourth day of trading at Oslo Børs after such approval and expire at 17:30h (Oslo time) two weeks thereafter.

7. Deadline for the payment of the new shares is 10 May 2010, or on the seventh day of trading at Oslo Børs after the expiry of the subscription period in the event that the subscription period is delayed as described in section 6 above. At the time of subscription, allottees who acquire shares against cash payment and who have a Norwegian bank account must provide the Company with a power of attorney to debit a specified Norwegian bank account for the subscription amount equal to the number of allotted shares. At the time of allotment, the allotted amount will be debited from the allottee's account. Debiting will be performed on or around the deadline.

8. Shareholders' preferential right to new shares is set aside as described in this decision.

9. The new shares will provide the same rights as existing shares in the Company, and rights will be valid from the time of registration of the capital increase in the Register of Business Enterprises, including the right to share dividends which are decided after the registration.

10. Section 3 in the Articles of Association will be changed in order to reflect the Company's share capital and number of shares after the share issue."

Disclaimer

- This Document includes and is based, *inter alia*, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. These statements and this Document are based on current expectations, estimates and projections about global economic conditions, the economic conditions of the regions and industries that are major markets for Aker BioMarine ASA and Aker BioMarine ASA's (including subsidiaries and affiliates) lines of business. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Important factors that could cause actual results to differ materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be major markets for Aker BioMarine's businesses, oil prices, market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time in the Document. Although Aker BioMarine ASA believes that its expectations and the Document are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in the Document. Aker BioMarine ASA is making no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the Document, and neither Aker BioMarine ASA nor any of its directors, officers or employees will have any liability to you or any other persons resulting from your use.
- The Aker BioMarine group consists of many legally independent entities, constituting their own separate identities. Aker BioMarine is used as the common brand or trade mark for most of this entities. In this document we may sometimes use "Aker BioMarine", "Group", "we" or "us" when we refer to Aker BioMarine companies in general or where no useful purpose is served by identifying any particular Aker BioMarine company.

The preferred partner

